Braze shorts cover at record pace after Salesforce deal

Short interest in BRZE fell 18.9% in a single week to 6.9% of free float, as short sellers raced to cover into a 56% price surge triggered by a Salesforce acquisition agreement. That weekly decline is 1.6 standard deviations below the company's typical weekly move over the past year.

Shorts retreat, but the story behind them is changing

From mid-September to mid-October, short interest ran above 8.5% of free float, peaking near 9.6 million shares on September 11. The covering began before the deal announcement fully priced in, with shorts trimming from 8.5 million to roughly 6.9 million between October 14 and 22. The ORTEX short score fell to 43.4 on October 22, down from 52.1 the week prior. That drop reflects both the covering and the shift in the lending market: availability has risen to 1,012%, up 89% in a week, meaning supply in the borrow pool is now far outstripping remaining demand. There are now more than 51 million shares available to borrow against under 7 million currently lent out. The borrow is not squeezed; cost to borrow sits at 0.50%, unchanged from its recent range.

Ten analysts downgrade, ten analysts raise their targets

The analyst action on October 21 was one of the more unusual days on record for BRZE. Ten firms downgraded the stock in a single session, citing the rally rather than any change in fundamentals. Barclays cut from Overweight to Equal-Weight, raising its target from $38 to $48. TD Cowen moved from Buy to Hold, lifting its target from $36 to $47.50. Stephens, DA Davidson, Wells Fargo, BTIG, Citigroup, Raymond James, Oppenheimer, and Stifel all followed the same pattern. The consensus now shows 19 Hold ratings and zero Buys, with the mean price target at $47.54. The stock closed at $45.88 on October 23, leaving implied upside of roughly 3.5%. Analysts are not calling it overvalued; they are saying it has arrived at fair value.

The EV/EBITDA multiple stood at 36.9 on October 26, up over a point in 30 days. The PE multiple has expanded 22.6 points over the same period, reflecting the price move rather than earnings revisions.

FMR adds aggressively, CTO sells on plan

FMR LLC disclosed a stake of 15% of shares outstanding, up from 12.4% at the prior filing, making it by far the largest institutional holder at roughly 16.9 million shares. Pictet Asset Management entered with 5 million shares in its most recent filing. On the other side, CTO Jonathan Hyman sold 285,000 shares on October 20 for approximately $12.9 million, all under a pre-arranged 10b5-1 plan. Planned sales are disclosure mechanics rather than conviction signals, but the net insider position over 90 days stands at minus $19.8 million across multiple executives.

Index removal on the clock

ORTEX forecasts an 84% probability that BRZE will be deleted from the Russell 2000 and Russell 3000 following the Salesforce acquisition. Estimated announcement date is March 23, 2027, with an effective date of March 31, 2027 (dates estimated). In 351 similar past changes, the median move from announcement to effective was minus 4.3%, with 80% of cases moving in the expected direction. Retail attention remains elevated: Wikipedia and ORTEX page traffic ran 4.8 standard deviations above their 90-day average as of October 19.

The specific date to watch is December 10, when Braze reports its next earnings. By then the acquisition timeline and any regulatory signals should be clearer, and options positioning, currently at a PCR of 0.27 against a 52-week low of 0.14, will reflect how much of the deal premium the market still treats as live.